Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate
- Registration Number
- NCT00880672
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The purpose of this study is to determine whether dutasteride may influence the expression of angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF) in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH).
- Detailed Description
A total of 41 patients awaiting transurethral resection of the prostate (TURP) will be divided into two groups (1:1); twenty patients will receive no medication and 21 will receive 0.5 mg dutasteride daily for 2 to 4 weeks until TURP. In both groups, the extent, intensity and intracellular location of hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)will be evaluated. Microvessel density will be also compared in the two groups.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 40
- informed consent
- 50 years old or older
- International Prostate Symptom Score (IPSS) >8
- Maximum flow rate (Qmax) <15 ml/s
- transurethral resection of the prostate (TURP)
- urethral catheter
- urinary tract infection (UTI)
- liver disease
- renal disease
- unexplained hematuria
- prostate specific antigen (PSA) > 4ng/ml (included if prostate biopsy was negative)
- interstitial cystitis
- bladder cancer or prostate cancer
- pelvic surgery or irradiation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description dutasteride dutasteride oral, 5mg, once per day, 2 weeks
- Primary Outcome Measures
Name Time Method HIF-1a and VEGF expression 2 weeks effects of dutasteride on the expression of angiogenesis markers in rat and human prostates
- Secondary Outcome Measures
Name Time Method